Donor leukocyte infusions in the treatment of chronic myeloid leukemia in relapse post bone marrow transplantation

Pathology

Volumn 28, Issue 1, 1996, Pages 51-53

  Hill, Geoffrey R ^a   Hart, Derek N J ^a   Moore, Andrea F ^a   Morris, Christine M ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

Bone marrow transplantation; Chronic myeloid leukemia; Donor leukocyte infusion; Graft versus host disease; Graft versus leukemia effect

Indexed keywords

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW APLASIA; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CASE REPORT; CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; LEUKOCYTE; MALE;

EID: 0030060436     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313029600169523     Document Type: Article

References (13)

1. Kantarjian HM, Smith TL, O'Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenic response to interferon-α therapy. Ann Intern Med 1995; 122: 254-61.
2. Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-5.
3. McGlave P, Arthur D, Haake R et al. Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation. J Clin Oncol 1987; 5: 1033-40.
4. Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104:155.
5. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806.
6. Devergie A, Reiffers J, Vernant JP et al. Long term follow-up after bone marrow transplantation for chronic myelogenous leukemia: factors associated with relapse. Bone Marrow Transplant 1990; 5: 379
7. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100-6.
8. Kumar L. Leukemia: management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 1994; 12: 1710-7.
9. Kolb HJ, Mittmuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-5.
10. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-83.
11. Bar BMAM, Schattenberg A, Mensink EJBM et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993; 11: 513-9.
12. Hertenstein B, Wiesthneth M, Novotny J et al. Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 1993; 56: 1114-8.
13. Drobyski WR, Keever CR, Roth MA et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-8.